Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Cancer Research

• Publication date

  1993-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 8402611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.

  1993cited by this paper
• The p53 protein is an unusually shaped tetramer that binds directly to DNA.

  1993cited by this paper
• Regulation of the specific DNA binding function of p53.

  1992cited by this paper
• Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

  1992cited by this paper
• Cancer risks from germline p53 mutations.

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper
• Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.

  1992cited by this paper
• A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

  1992cited by this paper
• Oncogenic forms of p53 inhibit p53-regulated gene expression.

  1992cited by this paper
• p53 function and dysfunction.

  1992cited by this paper
• A transcriptionally active DNA-binding site for human p53 protein complexes

  1992influential reference
• Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles.

  1992cited by this paper
• Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo.

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• Tumorigenic transformation of spontaneously immortalized fibroblasts from patients with a familial cancer syndrome.

  1991cited by this paper
• Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

  1990cited by this paper
• Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

  1990cited by this paper
• Genetic mechanisms of tumor suppression by the human p53 gene

  1990cited by this paper
• Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1.

  1987cited by this paper
• Genealogy of cancer in a family.

  1979cited by this paper

• Mutant p53: evolving perspectives

  2025cites this paper
• Somatic TP53 Mutations Drive T and NK Cell Dysfunction in AML and Can be Rescued by Reactivating Wild Type p53

  2025cites this paper
• Modulating the Immunosuppressive Tumor Microenvironment and Inhibiting Growth in Mutp53-Driven CRPC via STAT3 Pathway Blockade

  2025cites this paper
• p53, A Victim of the Prion Fashion

  2021cites this paper
• Mutant p53 oncogenicity - dominant-negative or gain-of-function?

  2020cites this paper
• Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

  2020cites this paper
• p53 tetramerization: at the center of the dominant-negative effect of mutant p53

  2020cites this paper
• Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis

  2020cites this paper
• A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

  2019cites this paper
• 2 The Functionality of p 53 in Thyroid Cancer

  2018cites this paper
• Open Access book publisher

  2017cites this paper
• Open Access book publisher

  2017cites this paper
• ANDROGEN-REGULATED GENE EXPRESSED IN PROSTATE TISSUE

  2017cites this paper
• Comparative Aspects of Osteosarcoma Pathogenesis in Humans and Dogs

  2015cites this paper
• Re-Engineered p53 Chimera with Enhanced Homo-Oligomerization That Maintains Tumor Suppressor Activity

  2014cites this paper
• Pathways by Tumorigenic Mutant p53 Inhibition of Stress-Inducible Kinase

  2014influential citation
• What mechanisms can't do: explanatory frameworks and the function of the p53 gene in molecular oncology.

  2013cites this paper
• Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

  2013cites this paper
• What Mechanisms Can ’ t Do : Explanatory Frameworks and the function of the p 53 in molecular oncology 1

  2013cites this paper
• A chimeric p53 evades mutant p53 transdominant inhibition in cancer cells.

  2013cites this paper
• Cancer cells and adaptive explanations

  2012cites this paper
• Chromosome instability and deregulated proliferation: an unavoidable duo

  2012cites this paper
• Cancer cells and adaptive explanations

  2012cites this paper
• The Functionality of p53 in Thyroid Cancer

  2012cites this paper
• Malignant Epithelial Neoplasms of the Large Bowel

  2012cites this paper
• The role of mutant p53 in human cancer

  2011cites this paper
• Contribution of the DNA binding domain of p53 to regulation of its stability

  2008cites this paper
• Molecular Pathogenesis of Osteosarcoma

  2007cites this paper
• Cancer Treatment and Research

  2005cites this paper
• SW480, a p53 double-mutant cell line retains proficiency for some p53 functions.

  2005cites this paper
• The p53 Tumor Suppressor Pathway and Cancer

  2005cites this paper
• Stage-specific gene expression during hepatocarcinogenesis in the rat

  2005cites this paper
• The Oncogenic Activity of p53 Mutants

  2005cites this paper
• Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.

  2004cites this paper
• Inhibition of Stress-Inducible Kinase Pathways by Tumorigenic Mutant p53

  2003influential citation
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1266 Analysis of Sun-Damaged Skin and Epidermal p53 Clones

  2003cites this paper
• p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas.

  2002cites this paper
• p 53 Transgenic Mice Are Highly Susceptible to 1 , 2-Dimethylhydrazine-induced Uterine Sarcomas 1

  2002cites this paper
• Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.

  2001cites this paper
• Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis

  2001cites this paper
• The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis

  2001cites this paper
• The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.

  2001cites this paper
• The temperature sensitive mutant p53-143ala extends in vitro life span, promotes errors in DNA replication and impairs DNA repair in normal human oral keratinocytes.

  2001cites this paper
• Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.

  2001cites this paper
• Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells.

  2000cites this paper
• Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

  2000cites this paper
• Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.

  1999cites this paper
• The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.

  1999cites this paper
• Cell cycle control, checkpoint mechanisms, and genotoxic stress.

  1999cites this paper
• Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li–Fraumeni syndrome fibroblast strains heterozygous for TP53 mutations

  1998cites this paper
• p53 and Brain Tumors: From Gene Mutations to Gene Therapy

  1998cites this paper
• [Germline mutations of the p53 gene].

  1997cites this paper
• Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53

  1997cites this paper
• Expression of Wild-type p53 Is Required for Efficient Global Genomic Nucleotide Excision Repair in UV-irradiated Human Fibroblasts*

  1997cites this paper
• Loss of function and p53 protein stabilization

  1997cites this paper
• Tumor suppressor genes and human cancer.

  1997cites this paper
• Radiation-induced bone and soft tissue sarcomas: clinical aspects and molecular biology.

  1997cites this paper
• Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

  1997cites this paper
• Faulty DNA polymerase delta/epsilon-mediated excision repair in response to gamma radiation or ultraviolet light in p53-deficient fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

  1996cites this paper
• Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53-/- mouse embryo fibroblasts.

  1996cites this paper
• The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy.

  1996cites this paper
• Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

  1995cites this paper
• Characterization of the signal transduction pathway mediating gamma ray-induced inhibition of DNA synthesis in human cells: indirect evidence for involvement of calmodulin but not protein kinase C nor p53.

  1995cites this paper
• The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.

  1995cites this paper
• Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation.

  1995cites this paper
• p53 gene mutations in pediatric brain tumors.

  1995cites this paper
• p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.

  1995cites this paper
• The p53 gene and its role in human brain tumors

  1995cites this paper
• Abnormal pattern of post-gamma-ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome.

  1995cites this paper
• Gene induction and adaptive responses in irradiated cells: Mechanisms and clinical implications

  1995cites this paper
• Colorectal cancer and the integrin family of cell adhesion receptors: current status and future directions.

  1994cites this paper
• The molecular biology of esophageal and gastric cancer and their precursors: oncogenes, tumor suppressor genes, and growth factors.

  1994cites this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cites this paper
• A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.

  1994cites this paper